Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials

免疫性血小板减少症 美罗华 埃尔特罗姆博帕格 医学 临床试验 重症监护医学 人口 罗米普洛斯蒂姆 免疫学 血小板生成素 伊库利珠单抗 免疫系统 血小板 抗体 补体系统 内科学 干细胞 遗传学 环境卫生 造血 生物
作者
Mahda Delshad,Zeinab Davoodi‐Moghaddam,Atieh Pourbagheri‐Sigaroodi,Mohammad Faranoush,Hassan Abolghasemi,Davood Bashash
出处
期刊:Thrombosis Research [Elsevier BV]
卷期号:235: 125-147 被引量:3
标识
DOI:10.1016/j.thromres.2024.02.005
摘要

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disorder that causes a significant reduction in peripheral blood platelet count. Fortunately, due to an increased understanding of ITP, there have been significant improvements in the diagnosis and treatment of these patients. Over the past decade, there have been a variety of proven therapeutic options available for ITP patients, including intravenous immunoglobulins (IVIG), Rituximab, corticosteroids, and thrombopoietin receptor agonists (TPO-RAs). Although the effectiveness of current therapies in treating more than two-thirds of patients, still some patients do not respond well to conventional therapies or fail to achieve long-term remission. Recently, a significant advancement has been made in identifying various mechanisms involved in the pathogenesis of ITP, leading to the development of novel treatments targeting these pathways. It seems that new agents that target plasma cells, Bruton tyrosine kinase, FcRn, platelet desialylation, splenic tyrosine kinase, and classical complement pathways are opening new ways to treat ITP. In this study, we reviewed the pathophysiology of ITP and summarized updates in this population's management and treatment options. We also took a closer look at the 315 ongoing trials to investigate their progress status and compare the effectiveness of interventions. May our comprehensive view of ongoing clinical trials serve as a guiding beacon, illuminating the path towards future trials of different drugs in the treatment of ITP patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
863发布了新的文献求助10
刚刚
刚刚
科研通AI65的应助被DW采纳,获得10
1秒前
cdercder的应助被开心德地采纳,获得10
2秒前
4秒前
岑兮完成签到,获得积分10
5秒前
shizaibide1314完成签到,获得积分10
5秒前
6秒前
朱占江完成签到,获得积分10
7秒前
南昌小霸王完成签到 ,获得积分10
7秒前
7秒前
三又一十八完成签到,获得积分10
7秒前
9秒前
cdercder的应助被开心德地采纳,获得10
9秒前
9秒前
鱼梓发布了新的文献求助10
10秒前
NexusExplorer的应助被白华苍松采纳,获得10
11秒前
云海老完成签到,获得积分10
11秒前
11秒前
12秒前
12秒前
12秒前
Pikus完成签到,获得积分10
13秒前
无所谓完成签到,获得积分10
14秒前
科研通AI65的应助被DW采纳,获得10
15秒前
枯桃发布了新的文献求助10
15秒前
15秒前
LMD发布了新的文献求助10
16秒前
16秒前
cdercder的应助被开心德地采纳,获得10
16秒前
我想当太空人完成签到,获得积分10
17秒前
action发布了新的文献求助10
17秒前
秋风的应助被emmm采纳,获得10
18秒前
19秒前
田12发布了新的文献求助10
19秒前
19秒前
22秒前
22秒前
彭于晏的应助被yang采纳,获得10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188339
求助须知:如何正确求助?哪些是违规求助? 9576127
关于积分的说明 21845709
捐赠科研通 7786389
什么是DOI,文献DOI怎么找? 3435292
关于科研通互助平台的介绍 2559588
邀请新用户注册赠送积分活动 2482196